- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.12. | Protagenic Therapeutics, Inc.: Results from Phase 1 Multiple-Dose Study of PT00114 | 208 | ACCESS Newswire | Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions NEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / Protagenic... ► Artikel lesen | |
| PROTAGENIC THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.11. | Protagenic Therapeutics receives Nasdaq non-compliance letter | 2 | Seeking Alpha | ||
| 27.11. | Protagonist Therapeutics: Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice | 231 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications... ► Artikel lesen | |
| 26.11. | Protagenic Therapeutics, Inc.\new - 10-Q, Quarterly Report | - | SEC Filings | ||
| 26.11. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 14.11. | Protagenic Therapeutics, Inc.\new - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | - | SEC Filings | ||
| 13.11. | Protagenic-Aktie steigt nach Abschluss der Phase-1-Dosierung | 2 | Investing.com Deutsch | ||
| 13.11. | Protagenic schließt Dosierungsphase in Phase-1-Studie für Medikament gegen Stresserkrankungen ab | 2 | Investing.com Deutsch | ||
| 13.11. | Protagenic completes dosing in phase 1 study of stress disorder drug | 2 | Investing.com | ||
| 13.11. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study | 208 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / November 13, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel therapeutics for stress-related neuropsychiatric and... ► Artikel lesen | |
| 31.10. | Protagenic Therapeutics reicht Klage zur Rückabwicklung der Übernahme von Phytanix Bio ein | 1 | Investing.com Deutsch | ||
| 31.10. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 2 | SEC Filings | ||
| 22.08. | Protagenic Therapeutics provides update on Form 10-Q filing timeline and Nasdaq compliance | 1 | Seeking Alpha | ||
| 22.08. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance | 472 | ACCESS Newswire | Delay Attributable to Merger-Related Financial Consolidation NEW YORK, NY / ACCESS Newswire / August 22, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX), a biopharmaceutical company developing novel... ► Artikel lesen | |
| 22.08. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 4 | SEC Filings | ||
| 21.08. | Protagenic Therapeutics stock soars after advancing PT00114 to multiple-dose trial | 7 | Investing.com | ||
| 21.08. | Protagenic Therapeutics: Aktie schießt nach Meilenstein bei klinischer Studie in die Höhe | 5 | Investing.com Deutsch | ||
| 21.08. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders | 344 | ACCESS Newswire | Dosing Completion Expected by End of August; Phase 2 Trial Expected to Begin in 1Q 2026 NEW YORK, NY / ACCESS Newswire / August 21, 2025 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical... ► Artikel lesen | |
| 13.08. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 1 | SEC Filings | ||
| 30.07. | Protagenic Therapeutics secures Japanese patent for epilepsy treatment | 1 | Investing.com |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,023 | -24,18 % | MEDIGENE AG stürzt ab - ich traue meinen Augen nicht! | ||
| CUREVAC | 3,502 | -14,46 % | EILMELDUNG: Curevac unter Druck - Anleger verlieren die Nerven! | ||
| VALNEVA | 3,576 | +0,06 % | Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ | IXCHIQ- was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after twelve months in both dose groups... ► Artikel lesen | |
| BIOFRONTERA | 2,460 | -7,17 % | BIOFRONTERA AG: Jetzt kippt das Gleichgewicht! | ||
| 4SC | 0,100 | -23,37 % | 4SC AG: Kapitalmaßnahmen mit Delisting ab Mitte Dezember | Die 4SC AG rechnet mit dem zeitnahen Wirksamwerden der von der Hauptversammlung am 19. September 2025 beschlossenen Kapitalmaßnahmen. Konkret soll die Kapitalherabsetzung auf null Euro mit gleichzeitiger... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 24,000 | -6,87 % | Laidlaw initiates coverage on Palatin Technologies stock with Buy rating | ||
| INOVIO PHARMACEUTICALS | 2,200 | +11,11 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,383 | +1,70 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy | RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,025 | -1,22 % | 1 Bold Prediction for Viking Therapeutics in 2026 | ||
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| EDITAS MEDICINE | 2,192 | +2,38 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| VAXART | 0,281 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen | |
| MICROBOT MEDICAL | 1,843 | -2,69 % | Microbot Medical Inc.: Microbot Medical Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio | Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | NSE - Affimed N.V. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| IMMUNITYBIO | 1,814 | -1,60 % | ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ-A First in Europe | ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, to receive a positive recommendation... ► Artikel lesen |
PROTAGENIC THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,470 Euro und damit -2,00 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROTAGENIC THERAPEUTICS INC finden Sie auf Wallstreet Online.